Clinical efficacy and pulmonary function improvement of double long-acting bronchodilator in the treatment of bronchiectasis complicated with chronic obstructive pulmonary disease

Cui Lijing; Zhang Shuqian; Wang Liang; Meng Jing

doi:10.3760/j.issn.1673-4777.2024.01.007

Abstract：Objective To analyze the clinical efficacy and pulmonary function improvement effect of double long-acting bronchodilator in the treatment of bronchiectasis complicated with chronic obstructive pulmonary disease(COPD).Methods A total of 100 patients with bronchiectasis complicated with COPD admitted to the Third Department of Respiratory Medicine,Hebei Chest Hospital from September 2019 to September 2021 were retrospectively studied by blind method,convenient sampling and control principle.According to different treatment methods,they were divided into observation group and control group,with 50 cases in each group.The control group was treated with tiotropium bromide inhalation powder spray,and the observation group was treated with tiotropium odaterol soft mist inhaler,all for 6 months.The clinical efficacy,pulmonary function,St.George's Respiratory Questionnaire(SGRQ)score,modified medical research council dyspnea index(mMRC)score,arterial blood gas index,total incidence of adverse reactions and 1-year readmission rate were compared between the two groups.Results The total effective rate of observation group was higher than that of control group[96.0％(48/50)vs 78.0％(39/50)](P=0.007).After 2,4,and 6 months of treatment,the forced vital capacity(FVC),forced expiratory volume in the first second(FEV,)and FEV1/FVC of observation group were higher than those of control group,the SGRQ score and mMRC score of observation group were lower than those of control group,the partial pressure of carbon dioxide of observation group was lower than that of control group,and the partial pressure of oxygen of observation group was higher than that of control group(all P＜0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P=1.000).The 1-year readmission rate of observation group was lower than that of control group[2.0％(1/50)vs 16.0％(8/50)](P=0.036).Conclusions The double long-acting bronchodilator tiotropium odaterol soft mist inhaler has a significant effect on improving pulmonary function and arterial blood oxygen status in patients with bronchiectasis complicated with COPD,which can effectively relieve the symptoms of dyspnea and reduce the readmission rate,and has certain safety.